MindMed discloses prelim cash & investments of $209.1M

Mind Medicine (MindMed) Inc. disclosed preliminary liquidity.

Rhea-AI Filing Summary

Mind Medicine (MindMed) Inc. disclosed preliminary liquidity. The company reported estimated unaudited cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025. This figure was included in a prospectus supplement and an updated corporate presentation posted on October 29, 2025.

Management emphasized that the estimate is preliminary and subject to completion, and that the company’s independent auditor, KPMG LLP, has not audited, reviewed, or compiled this information. The company noted that adjustments may be required once customary procedures are completed.

MindMed also filed the corporate presentation as Exhibit 99.1, making the materials available for investors seeking additional context on its financial position.

Insights

Equity capital markets analyst

Preliminary liquidity of $209.1M; unaudited and subject to change.

MindMed provided an early look at its liquidity, stating estimated cash, cash equivalents and investments of $209.1 million as of September 30, 2025. This disclosure was paired with a prospectus supplement and a posted corporate presentation, a common practice to update investors on available resources.

The company notes the figure is preliminary and unaudited, with KPMG LLP having performed no procedures. That caveat means the number may change once final closing processes are completed.

The filing adds transparency around liquidity but does not specify operating burn, runway, or proceeds. Subsequent filings may provide finalized quarter-end balances.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did MNMD disclose in this 8-K?

MindMed disclosed estimated unaudited cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025.

Is the $209.1 million figure for MNMD audited?

No. The company states the figure is preliminary and unaudited, and KPMG LLP has not audited, reviewed, or compiled it.

Why did MNMD file a prospectus supplement and presentation?

To include and share the preliminary liquidity estimate; the prospectus supplement and an updated corporate presentation convey this information.

When was the MNMD corporate presentation posted?

The presentation was posted on October 29, 2025 and filed as Exhibit 99.1.

Does this 8-K include MNMD earnings results?

No. It provides a preliminary liquidity estimate and references a prospectus supplement and corporate presentation.

Who is MNMD’s independent auditor mentioned in the filing?

KPMG LLP is the independent registered public accounting firm referenced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/29/2025 - 04:11 PM Learn about SEC filing dates

false 0001813814 A1 0001813814 2025-10-29 2025-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

MIND MEDICINE (MINDMED) INC.

(Exact Name of Registrant as Specified in its Charter)

British Columbia		001-40360		98-1582438
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

One World Trade Center Suite 8500 New York, New York		10007
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 220-6633

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares		MNMD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2025, Mind Medicine (MindMed), Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) and, as discussed elsewhere in this Current Report on Form 8-K, posted an updated corporate presentation on its website (the “Presentation”). The Prospectus Supplement and Presentation disclose the Company’s estimated preliminary financial information of cash, cash equivalents and investments of approximately $209.1 million as of September 30, 2025.

This estimate of cash, cash equivalents and investments is preliminary and subject to completion. As a result, this unaudited preliminary financial information reflects the Company’s preliminary estimate with respect to such information, based on information currently available to the Company’s management, and may vary from the Company’s actual financial position as of September 30, 2025. The unaudited preliminary cash, cash equivalents and investments included in the Prospectus Supplement, the Presentation and this Current Report on Form 8-K have been prepared by, and are the responsibility of, the Company’s management. The Company’s independent registered public accounting firm, KPMG LLP, has not audited, reviewed, compiled or completed its procedures with respect to such unaudited financial information and, accordingly, KPMG LLP does not express an opinion or any other form of assurance with respect thereto. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the financial information set forth above.

Item 8.01 Other Events.

On October 29, 2025, the Company posted the Presentation on its website. A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d)       Exhibits

Exhibit No.		Description
99.1		Corporate Presentation, posted October 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MIND MEDICINE (MINDMED) INC.
Date:	October 29, 2025	By:	/s/ Robert Barrow
			Name:	Robert Barrow
			Title:	Chief Executive Officer